{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:10:07Z","timestamp":1774465807502,"version":"3.50.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Factor XIa inhibitors are a promising novel class of anticoagulants that attenuate pathological thrombosis with minimal interference with hemostasis. These effects contrast with those of conventional anticoagulants, which may exhibit adverse events of untoward bleeding precluding treatment in some patients. A variety of investigational pharmacological modalities have been developed and studied to target factor XIa.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Asundexian is a small molecule inhibitor of factor XIa that has been evaluated in several clinical studies. It has been studied as an oral, once-daily medication and found to inhibit approximately 90% of factor XIa activity at doses of 20 to 50 mg. Phase 2 trials have demonstrated the potential for improved safety compared to standard of care in certain treatment settings, such as in atrial fibrillation. For other indications, such as noncardioembolic stroke and acute myocardial infarction, asundexian has been used in addition to background antiplatelet therapy. In these instances, asundexian did not show a difference in the incidence of bleeding events compared to placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Phase 3 trials have recently been launched; however, the OCEANIC-AF trial was prematurely discontinued due to inefficacy of asundexian vs apixaban for stroke prevention in atrial fibrillation. Another phase 3 trial, OCEANIC-AFINA, is planned to compare asundexian to placebo in patients with atrial fibrillation at high risk for stroke who are deemed ineligible for anticoagulation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae182","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T15:13:39Z","timestamp":1720797219000},"page":"1222-1229","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the therapeutic utility of the factor XIa inhibitor asundexian"],"prefix":"10.1093","volume":"81","author":[{"given":"Jocelyn","family":"Edwards","sequence":"first","affiliation":[{"name":"ChristianaCare , Newark, DE ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Corey","sequence":"additional","affiliation":[{"name":"Ochsner LSU Health Shreveport , Shreveport, LA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C","family":"Coons","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy , Pittsburgh, PA"},{"name":"UPMC Presbyterian Hospital , Pittsburgh, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"1","key":"2024121018582530700_CIT0001","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2024121018582530700_CIT0002","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2024121018582530700_CIT0003","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2024121018582530700_CIT0004","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"9","key":"2024121018582530700_CIT0005","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2024121018582530700_CIT0006","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2125.2006.02806.x","article-title":"Warfarin: almost 60 years old and still causing problems","volume":"62","author":"Pirmohamed","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2024121018582530700_CIT0007","doi-asserted-by":"crossref","first-page":"e2242964","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"13","key":"2024121018582530700_CIT0008","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2015.01.049","article-title":"Practical management of anticoagulation in patients with atrial fibrillation","volume":"65","author":"Kovacs","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2024121018582530700_CIT0009","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2024121018582530700_CIT0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"2024121018582530700_CIT0011","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood-2016-09-692996","article-title":"Emerging anticoagulant strategies","volume":"129","author":"Fredenburgh","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2024121018582530700_CIT0012","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2009-09-199182","article-title":"Structure and function of factor XI","volume":"115","author":"Emsley","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2024121018582530700_CIT0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2024121018582530700_CIT0014","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"2024121018582530700_CIT0015","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2024121018582530700_CIT0016","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","article-title":"Overview of the new oral anticoagulants: opportunities and challenges","volume":"35","author":"Yeh","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"2024121018582530700_CIT0017","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2024121018582530700_CIT0018","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bcp.15230","article-title":"Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: a randomized phase 1 multiple-dose study","volume":"88","author":"Kubitza","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2024121018582530700_CIT0019","author":"Bayer","year":"2021"},{"key":"2024121018582530700_CIT0020","author":"Bayer","year":"2023"},{"issue":"10333","key":"2024121018582530700_CIT0021","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"issue":"10357","key":"2024121018582530700_CIT0022","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"2024121018582530700_CIT0023","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"2024121018582530700_CIT0024","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2024121018582530700_CIT0025","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"23","key":"2024121018582530700_CIT0026","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2024121018582530700_CIT0027","author":"Bayer","year":"2024"},{"key":"2024121018582530700_CIT0028","author":"Bayer","year":"2024"},{"key":"2024121018582530700_CIT0029","author":"Bayer","year":"2023"},{"issue":"8","key":"2024121018582530700_CIT0030","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week","volume":"81","author":"Harrington","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2024121018582530700_CIT0031","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ahj.2014.07.002","article-title":"Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)","volume":"168","author":"O\u2019Brien","year":"2014","journal-title":"Am Heart J"},{"key":"2024121018582530700_CIT0032","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ahj.2017.08.011","article-title":"International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries","volume":"194","author":"Steinberg","year":"2017","journal-title":"Am Heart J."},{"issue":"6","key":"2024121018582530700_CIT0033","doi-asserted-by":"crossref","first-page":"e014108","DOI":"10.1161\/JAHA.119.014108","article-title":"Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study","volume":"9","author":"Sanghai","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2024121018582530700_CIT0034","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/bloodadvances.2020003560","article-title":"Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry","volume":"5","author":"Bassand","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2024121018582530700_CIT0035","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the Chest guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"2024121018582530700_CIT0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42444-021-00053-9","article-title":"Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants","volume":"23","author":"Park","year":"2022","journal-title":"Int J Arrhythmia"},{"key":"2024121018582530700_CIT0037","doi-asserted-by":"crossref","first-page":"661955","DOI":"10.3389\/fneur.2021.661955","article-title":"Hemorrhagic transformation in ischemic stroke and the role of inflammation","volume":"12","author":"Spronk","year":"2021","journal-title":"Front Neurol"},{"issue":"4","key":"2024121018582530700_CIT0038","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/ijs.12007","article-title":"Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation","volume":"10","author":"Tu","year":"2015","journal-title":"Int J Stroke"},{"issue":"1","key":"2024121018582530700_CIT0039","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"2024121018582530700_CIT0040","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1055\/a-1778-1083","article-title":"State-of-the-art mini review: dual-pathway inhibition to reduce arterial and venous thromboembolism","volume":"122","author":"Goldin","year":"2022","journal-title":"Thromb Haemost"},{"issue":"14","key":"2024121018582530700_CIT0041","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae182\/58575498\/zxae182.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/24\/1222\/60956201\/zxae182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/24\/1222\/60956201\/zxae182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T19:56:58Z","timestamp":1733860618000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/81\/24\/1222\/7712713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":41,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,7,12]]},"published-print":{"date-parts":[[2024,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae182","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,15]]},"published":{"date-parts":[[2024,7,12]]}}}